New combo therapy offers hope for aggressive lymphoma patients
NCT ID NCT07460362
First seen Mar 10, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This study tests a combination of two drugs, glofitamab and lenalidomide, in 43 adults with a type of blood cancer called mantle cell lymphoma that has returned or not responded to treatment, especially after a BTK inhibitor stopped working. Participants receive glofitamab through an IV and take lenalidomide pills at home. The goal is to see how many patients achieve a complete or partial response by the end of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100191, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.